Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
暂无分享,去创建一个
Shibing Deng | J. Ahn | M. Ahn | Keunchil Park | Dong-Wan Kim | E. Schoenmakers | W. Kim | Yoon-La Choi | Y. Koh | T. Kim | Se-Hoon Lee | Mao Mao | D. Chung | Jong-Mu Sun | H. Go | Maruja Lira | B. Jang | Donghui Huang
[1] S. Tripp,et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optima , 2012, Archives of pathology & laboratory medicine.
[2] A. Atherly,et al. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers , 2012, British Journal of Cancer.
[3] Hiroshi Sakamoto,et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.
[4] L. Waldron,et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes , 2011, BMC biotechnology.
[5] P. Jänne,et al. Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer , 2011, Clinical Cancer Research.
[6] J. Bruey,et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. , 2011, Cancer genetics.
[7] W. Franklin,et al. Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.
[8] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[9] P. Jänne,et al. The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.
[10] A. Iafrate,et al. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.
[11] M. Varella‐Garcia,et al. ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[14] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[15] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[16] Afshin Mashadi-Hossein,et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System , 2009, BMC Research Notes.
[17] John M. Maris,et al. Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.
[18] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[19] Yuki Togashi,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.
[20] Francesca Demichelis,et al. EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.
[21] Jennifer L. Osborn,et al. Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.
[22] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[23] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[24] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[25] A. Rosenwald,et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. , 1999, Blood.
[26] C. Griffin,et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. , 1999, Cancer research.
[27] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.